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In this study, we investigated the role of PI4P synthesis by the phosphatidylinositol 4-kinases, PI4KIIa and PI4KIIIb, in epidermal
growth factor (EGF)-stimulated phosphoinositide signaling and cell survival. In COS-7 cells, knockdown of either isozyme by
RNA interference reduced basal levels of PI4P and PI(4,5)P2, without affecting receptor activation. Only knockdown of PI4KIIa
inhibited EGF-stimulated Akt phosphorylation, indicating that decreased PI(4,5)P2 synthesis observed by loss of either isoform
could not account for this PI4KIIa-speciﬁc effect. Phospholipase Cc activation was also differentially affected by knockdown of
either PI4K isozyme. Overexpression ofkinase-inactive PI4KIIa,which induces defectiveendosomal trafﬁcking without reducing
PI(4,5)P2levels, alsoreduced Aktactivation. Furthermore,PI4KIIaknockdownprofoundlyinhibitedcell proliferation andinduced
apoptosis as evidenced by the cleavage of caspase-3 and its substrate poly(ADP-ribose) polymerase. However, in MDA-MB-231
breast cancer cells, apoptosis was observed subsequent to knockdown of either PI4KIIa or PI4KIIIb and this correlated with
enhanced proapoptotic Akt phosphorylation. The differential effects of phosphatidylinositol 4-kinase knockdown in the two cell
lines lead to the conclusion that phosphoinositide turnover is inhibited through PI4P substrate depletion, whereas impaired
antiapoptotic Akt signaling is an indirect consequence of dysfunctional endosomal trafﬁcking.
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Receptor-dependent phosphoinositide signaling pathways
control cell survival and are frequently deregulated in
cancer.
1,2 In this report, we focus on phosphoinositide
signaling mediated by the epidermal growth factor receptor
(EGFR), a receptor tyrosine kinase that is overexpressed in a
variety of solid tumors and is the target for multiple cancer
therapeutics.
3 Ligand stimulation of EGFR leads to activation
of two important phosphoinositide signaling cascades. The
ﬁrst pathway operates via phospholipase Cg (PLCg)
isozymes, which hydrolyze phosphatidylinositol (4,5)-bispho-
sphate (PI(4,5)P2) to produce the second messengers,
inositol-trisphosphate and diacylglycerol (reviewed in Bunney
andKatan
2).EnhancedPLCgsignalinghasbeenimplicatedin
upregulated cell motility and metastasis.
4,5 The second
pathway is mediated by phosphoinositide 3-kinase (PI3K)
isozymes, which phosphorylate PI(4,5)P2 on the D3 position
to produce phosphatidylinositol (3,4,5)-trisphosphate
(PI(3,4,5)P3) (reviewed in Bunney and Katan
2). PI(3,4,5)P3
stimulates the activity of phosphoinositide-dependent kinase 1,
whichinturnphosphorylates andactivatesAkt(alsoknownas
PKB), a serine/threonine kinase that regulates a range of
proteins such as BAD that are essential for cell survival.
6
Dysfunctional PI3K signaling is associated with defective cell
proliferation and motility, and this pathway isa major target for
chemotherapeutic intervention in a diverse range of malig-
nancies.
1However,thereisalsoagrowingawarenessthatthe
proliferation of cancer cells with normal PI3K signaling is
insensitive to Akt inhibition.
7
Compared with PI(4,5)P2, cellular levels of PI(3,4,5)P3,
even in stimulated cells, are very low.
8 Nevertheless, there is
evidence thatPI3KandPLCg cancompeteforacommonpool
of PI(4,5)P2, substrate, for example, during VEGF-stimulated
angiogenesis.
9 Given that PI4Ks can potentially supply
substrate into both phosphoinositide signaling pathways, we
sought to explore the roles of these enzymes as possible
upstream regulators of PLC and Akt activation. Furthermore,
as the syntheses of both PI(4,5)P2
10,11 and PI(3,4,5)P3
have been associated with antiapoptotic signaling, we
investigatedwhethertargetingPI4Psynthesiscouldmodulate
cell survival.
There are four PI4K isozymes in mammalian cells: the type
III PI4Ks, PI4KIIIa and PI4KIIIb, which can be inhibited by
wortmannin and are structurally homologous to the PI3K
family, and the type II PI4Ks, PI4KIIa and PI4KIIb, which are
wortmannin insensitive and structurally distinct from other
phosphoinositide kinases.
12 Despite their similar catalytic
activity, the PI4Ks have non-overlapping localizations within
cells and perform isoform-speciﬁc functions.
12 In this study,
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different regions of the trans-Golgi network
13,14 and to
endosomes.
14–16
PI4KIIa
14–16 and PI4KIIIb have been implicated in Golgi-
endosomal trafﬁcking,
17–20 and PI4KIIa has been shown to
regulate Wnt3a
21 and proangiogenic vascular endothelial
growth factor signaling.
22 However, investigations in to the
roles of different PI4K isoforms
23 and Golgi-associated PI4P
synthesis
24 in G-protein-coupled receptor (GPCR)-mediated
signaling indicated only minor roles for PI4KIIa and PI4KIIIb.
There are precedents for PI4K-dependent cell survival in
yeast
25 and zebraﬁsh,
26 and we recentlyreported that PI4KIIa
homozygous knockout mice develop late-onset neurodegen-
eration.
27 Although PI4KIIa and PI4KIIIb are known to be
important for phosphoinositide-dependent intracellular mem-
brane trafﬁcking, the roles of these enzymes in the regulation
of antiapoptotic signaling have not been explored. On the
basis of what is already established for these enzymes, it is
most likely they modulate phosphoinositide signaling through
effects on phosphoinositide substrate supply and/or vesicular
trafﬁcking.
Our main aim in this study was to investigate whether
decreased supply of PI4P substrate was important for
epidermal growth factor (EGF)-stimulated PLC and Akt
signaling, and consequently cell survival. A previous
study using LY294002 at concentrations sufﬁcient to
inhibit PI4KIIIs indicated that the EGF-stimulated calcium
response required both PI4KII and PI4KIII activity.
28 This
suggests a key difference between EGFR and GPCR
signaling, and possibly a more prominent role for PI4KIIs
in EGF-dependent phosphoinositide signaling. However,
nothing is known about the PI4K isoform dependency
of EGF-stimulated PI3K signaling. We investigated the
relationships between PI4Ks, PI(4,5)P2 levels, Akt activation
and cell proliferation using COS-7 and MDA-MB-231 cell
lines, which have contrasting dependencies on Akt activation
for cell survival.
29,30 COS-7 cells are an SV40-transformed
African green monkey kidney ﬁbroblast cell line that
proliferates in response to EGF treatment through a mechan-
ism requiring Akt activation.
29 On the other hand, proliferation
of MDA-MB-231 breast cancer cells is insensitive to
EGF stimulation
30 or Akt inhibition.
7 Moreover, enhanced
AktphosphorylationisassociatedwithimpairedMDA-MB-231
cell survival.
31 MDA-MB-231 are also an example of a
triple-negative breast cancer cells, which express neither
hormone receptors nor HER2 and are therefore difﬁcult to
target with current chemotherapeutic strategies. Another
important feature of MDA-MB-231 cells is that they
are normal for class 1A PI3K and PTEN, and are not addicted
to Akt signaling.
7 We found that RNA interference (RNAi)-
mediated PI4KIIa knockdown induced apoptosis and
reduced cell proliferation in both cell lines. PI4KIIa depletion
led to cell-speciﬁc effects on Akt phosphorylation that were
independent of changes to total cellular PI4P and PI(4,5)P2
levels. However, loss of the PI4KIIIb isoform induced
apoptosis only in MDA-MB-231 cells and this correlated with
enhanced Akt phosphorylation and not with phosphoinositide
depletion. These data reveal novel insights into the functions
of PI4KIIa and PI4KIIIb in antiapoptotic signaling and cell
survival.
Results
Loss of PI4KIIa results in activation of caspase-3 and
cleavage of PARP. We employed established RNAi
methodology
14,15,32 to deplete PI4KIIa or PI4KIIIb, and
investigated whether loss of either PI4K had consequences
for COS-7 cell survival and proliferation. We found that loss
of PI4KIIa but not PI4KIIIb resulted in proteolytic activation of
caspase-3 and cleavage of its substrate poly(ADP-ribose)
polymerase (PARP) at 72h, when there is maximum
depletion of PI4KIIa (Figure 1a). In addition, cell
proliferation was profoundly reduced by loss of PI4KIIa
(Figure 1b). Compared with mock-transfected cells,
knockdown of PI4KIIa reduced cell proliferation
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Figure 1 PI4KIIa is required for cell survival in COS-7 cells. COS-7 cells were
mock transfected or transfected with PI4KIIa or PI4KIIIb siRNA. (a) Time course of
PI4K knockdown. Effects of PI4KIIa or PI4KIIIb depletion on caspase-3 activation
and cleavage of its substrate PARP. Akt levels over RNAi time course. Cells were
analyzed by immunoblotting at 0, 24, 48 and 72h after transfection. Representative
blots from 2–5 independent experiments are shown. (b) Effects of PI4KIIa or
PI4KIIIb depletionon cellproliferation. Livecellcountsweredeterminedat0, 24,48
and72haftertransfection.Datapresentedaremeans±S.E.M.offourindependent
experiments. *Po0.05
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Cell Death and Disease43.2±10.4% at 72h after transfection (n¼4, Po0.05 at
72h). In contrast to PI4KIIa, knockdown of PI4KIIIb had no
effect on cell proliferation. These results indicate an isoform-
speciﬁc role for PI4KIIa in protecting COS-7 cells from
caspase-mediated apoptosis. We also found that there were
no changes in total Akt levels over the 72h time course
(Figure 1a), indicating that PI4KIIa does not directly regulate
Akt stability or expression.
RNAi knockdown of PI4KIIa inhibits EGF activation of
Akt. Given that knockdown of PI4KIIa inhibited COS-7 cell
proliferation, we examined the relationship between PI4K
depletion and antiapoptotic EGF-stimulated phosphoinositide
signaling. Maximum knockdown of PI4KIIa and PI4KIIIb
were observed at 72h after transfection (Figure 1a),
therefore this time point was chosen for stimulations with
EGF. siRNA-treated cells were serum starved and stimulated
with 100ng/ml EGF or vehicle control for 10min, then
harvested in SDS-PAGE sample buffer. The cell lysates
were analyzed by immunoblotting against PI4KIIa and
PI4KIIIb to verify target knockdown, and phospho-speciﬁc
antibodies for EGFR, PLCg and Akt to investigate signaling
activation. Phosphorylation of Akt reports receptor-
stimulated synthesis of PI(3,4,5)P3 through the PI3K
pathway, whereas phosphorylation of PLCg depends on
EGFR activation. PI4P produced by PI4KIIa has the potential
to supply substrate to both the PI3K and PLC pathways.
As shown in Figure 2b, loss of PI4KIIa but not PI4KIIIb
resulted in reduced basal and EGF-stimulated levels of
phospho-Akt. This suggests a speciﬁc requirement for the
PI4KIIa isoform in EGF-dependent PI3K signaling. We
observed no reduction in agonist-stimulated EGFR phosphor-
ylation or EGFR levels (Figure 2b), thus the diminished levels
of phospho-Akt activation were not due to inhibition of
receptor activation or reduced receptor levels. Furthermore,
depletion of the PI4KIIa isoform did not inhibit EGF-stimulated
PLCg phosphorylation (Figure 2b). However, loss of PI4KIIIb
resulted in enhanced basal PLCg phosphorylation and
reduced responsiveness to EGF. These results demonstrate
that loss of the PI4KIIa isoform speciﬁcally affected EGF-
dependent Akt signaling.
Interestingly, following serum starvation, knockdown of
PI4KIIa but not PI4KIIIb resulted in a major fall in Akt levels, a
small decrease in PLCg and no change to total EGFR levels
(Figure 2b). Although reduced total Akt levels accounted for
decreased Akt activation in COS-7 cells, the residual Akt
protein was still phosphorylated in response to EGF addition
(Figure 2b). These results indicate that EGFR coupling to the
PI3K pathway was not inhibited through loss of PI4KIIa and
suggest that PI4KIIa may regulate Akt activation indepen-
dently of PI(4,5)P2 substrate provision to PI3K.
PI4KIIa and PI4KIIIb supply PI4P and PI(4,5)P2 for EGF-
stimulated phosphoinositide metabolism. We investi-
gated whether the diminished EGF-dependent Akt
activation with PI4KIIa knockdown is a result of reduced
phosphoinositide synthesis. [
32P]phosphate metabolic
radiolabeling studies were performed on siRNA-treated
COS-7 cells. EGF (100ng/ml) stimulation for 10min
resulted in a signiﬁcant fall in [
32P]PI4P to 57.5±14.1%
(n¼4, Po0.05) of basal levels in mock-transfected cells
(Figure 3a). Cells treated with siRNA against PI4KIIa or
PI4KIIIb had reduced basal levels of [
32P]PI4P, which were,
respectively, 36.4±13.9 (n¼4, Po0.01) and 27.5±4.8%
(n¼4, Po0.0001) of control levels (Figure 3a). In addition,
the EGF-stimulated [
32P]PI4P response was inhibited by
RNAi depletion of PIKIIa or PI4KIIIb (n¼4, Figure 3a). Loss
of either PI4K isoform also led to substantial falls in basal
[
32P]PI(4,5)P2, to 50.2±11.3% (n¼4, Po0.01) and
41.2±15.5% (n¼4, Po0.01) of control levels for PI4KIIa
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Figure 2 Knockdown of PI4KIIa inhibits EGF-induced Akt activation. COS-7
cells were mock transfected or transfected with PI4KIIa or PI4KIIIb siRNA. After
72h of transfection, the cells were stimulated with 100ng/ml EGF or vehicle control
for 10min and analyzed by immunoblotting. (a) Levels of knockdown of PI4KIIa or
PI4KIIIb with siRNA treatment. Triplicate wells for each condition are shown.
(b) PI4KIIa knockdown inhibits Akt phosphorylation but not EGFR or PLCg
phosphorylation. Loss of PI4KIIa leads to a large reduction in Akt levels following
serum starvation. Representative blots from two 2–10 independent experiments
are shown
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Cell Death and Diseaseand PI4KIIIb respectively (Figure 3b). Notably, knockdown of
PIKIIa or PI4KIIIb abolished the [
32P]PI(4,5)P2 response to
EGF (Figure 3b). Thus, knockdown of either PI4K isozyme
blocks PI(4,5)P2 turnover without any inhibition of EGF-
stimulated PLCg phosphorylation (Figure 3). These results
demonstrate that both PI4KIIa and PI4KIIIb can supply PI4P to
PI4P5K during EGFR activation.
Kinase-inactive PI4KIIa inhibits EGF activation of
Akt. To conﬁrm the ﬁnding that regulation of Akt by
PI4KIIa is not due to changes in total cellular PI4P and
PI(4,5)P2 levels, we utilized the lipid kinase-inactive mutant
version (K152A)PI4KIIa.
15 It has been shown that
overexpression of kinase-inactive PI4KIIa does not lead to
any measurable changes to either total cellular PI4P or
PI(4,5)P2 levels,
14 but results in defective endosomal
trafﬁcking.
16,33 Overexpression of catalytically inactive
PI4KIIa leads to reduced transferrin uptake,
33 and
compared with wild-type enzyme, the inactive enzyme
colocalizes less with AP-3 and LAMP1, and more with AP-1
and transferrin receptor.
16 COS-7 cells were transiently
transfected with constructs encoding GFP-(WT)PI4KIIa or
GFP-(K152A)PI4KIIa, serum starved and stimulated with
100ng/ml EGF or vehicle control for 0–10min. The cells were
harvested and analyzed by immunoblotting. Compared with
wild-type PI4KIIa-expressing cells, (K152A)PI4KIIa inhibited
EGF-stimulated Akt phosphorylation but not PLCg
phosphorylation (Figure 4). EGFR levels were unchanged,
consistent with the observation that kinase-inactive PI4KIIa
does not inhibit EGFR endocytosis.
15 These data suggest
that PI4KIIa activity is important for EGF-stimulated Akt
activation, but likely acts via endosomal trafﬁcking
changes
16,33 rather than depletion of PI(4,5)P2.
14
PI4K-dependent cell survival in MDA-MB-231 cells. We
repeated these experiments in the triple-negative breast
cancer cell line MDA-MB-231. As in COS-7 cells, RNAi
knockdown of PIKIIa or PI4KIIIb was maximal at 72h after
transfection (Figure 5a). Relative to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), both PI4K isoforms
were expressed at higher levels in COS-7 cells, illustrating a
cell type difference (Figure 5b).
We investigated whether MDA-MB-231 cell survival
depended on PI4K levels, by assessing PARP cleavage in
RNAi-treated cells. Unlike COS-7 cells, there was a low level
of PARP cleavage evident in mock-transfected cells, which
was augmented by knockdown of either PI4KIIa or PI4KIIIb
(Figure 6a). In addition, the onset of cleavage was earlier, and
was evident by 48h after transfection (Figure 6a). The lack of
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Figure 3 Loss of PI4KIIa or PI4KIIIb reduces pools of signaling lipids and
affects EGF-induced phosphoinositide metabolism. COS-7 cells were mock
transfected or transfected with PI4KIIa or PI4KIIIb siRNA. After 72h, they were
labeled with [
32P]phosphate and stimulated with 100ng/ml EGF or vehicle control
for 10min. Cells were harvested and [
32P]-labeled lipids were analyzed by TLC.
Effects of PI4K RNAion (a)[
32P]-labeledPI4P and (b)[
32P]-labeled PI(4,5)P2. Data
presented are means±S.E.M. from four independent experiments. *Po0.05,
**Po0.01, ***Po0.0001; NS, not signiﬁcant
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Figure 4 Kinase-inactive (K152A)PI4KIIa selectively inhibits Akt activation.
COS-7 cells were transfected with GFP-PI4KIIa or catalytically inactive GFP-
(K152A)PI4KIIa. Cells were serum starved, stimulated with 100ng/ml EGF and cell
lysates were analyzed by immunoblotting. Representative blots from three
independent experiments are shown
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Cell Death and Diseaseisoform selectivity in protecting MDA-MB-231 cells from
apoptosis was conﬁrmed by the results of TUNEL assays,
which allows quantiﬁcation of cell death by labeling of DNA
strand breaks. Loss of either PI4K isoform induced large
ﬁvefold increases in cell death at 72h after transfection
(Figure 6b and c). In all, 5.6±0.7% of mock-transfected cells
were apoptotic, compared with 26.1±3.2% for PI4KIIa
knockdown and 22.7±2.9% for PI4KIIIb knockdown
(Figure 6c).
Similar to the apoptosis data, proliferation assays showed
that loss of either PI4K isoform led to decreased cell
proliferation, with a 28.4% reduction for PI4KIIa and 26.1%
for PI4KIIIb (Po0.05 for either PI4K compared with mock at
72h, Figure 6d). Taken together, the results indicate an
antiapoptotic role for PI4KIIa in both cell types, whereas the
antiapoptotic activity of PI4KIIIb is cell type dependent.
Role of PI4K isoforms in MDA-MB-231 EGFR signal-
ing. Unlike COS-7 cells, MDA-MB-231 cells do not
proliferate in response to EGF
30 and their proliferation is
insensitive to Akt inhibition.
7 With this in mind, we
investigated whether there were any correlations between
MDA-MB-231 cell survival, EGF signaling and PI4K-
dependent phosphoinositide levels. As might be
expected,
30 we observed high basal levels of EGFR
phosphorylation in MDA-MB-231 cells, which were only
slightly increased following agonist stimulation. However,
EGF addition augmented Akt and PLCg phosphorylation,
indicating that receptor-activated phosphoinositide signaling
was functional in MDA-MB-231 cells (Figure 7a). Knockdown
of either PI4KIIa or PI4KIIIb resulted in increased Akt
activation in response to EGF (Figure 7a). EGF-stimulated
PLCg activation was not enhanced following loss of either
PI4K isoform (Figure 7a). Similar to COS-7 cells, we found
that knockdown of either PI4KIIa or PI4KIIIb in MDA-MB-231
cells markedly reduced basal levels of [
32P]PI4P and
[
32P]PI(4,5)P2, which makes it very unlikely that EGF-
stimulated Akt phosphorylation is directly dependent on
PI4P synthesis by either isozyme. The recent ﬁnding that
Akt activation in MDA-MB-231 cells induces apoptosis
31
leads us to conclude that loss of either PI4K in this cell
line results in cell death through enhanced proapoptotic
signaling.
Discussion
The aim of this study was to examine the roles of PI4KIIa and
PI4KIIIb in EGF-dependent phosphoinositide signaling and
cell survival. As exempliﬁed by the effects of PI4KIIIb loss in
COS-7 cells, large-scale and sustained depletion of cellular
PI(4,5)P2 does not necessarily lead to caspase-dependent
apoptosis or inhibited Akt activation. This differs from a
published study, indicating an antiapoptotic role for PI(4,5)P2
through direct caspase-3 inhibition.
11 Additionally, we demon-
strate that depletion of PI4P and PI(4,5)P2 by either PI4K
decreases EGF-stimulated phosphoinositide turnover without
affecting PLC activation. This is consistent with previous work
on EGF-stimulated calcium signaling, suggesting roles for
type II and type III PI4Ks in PLC signaling
28 but differs from
GPCR signaling where PI4KIIa loss has only minor effects on
the PLCb-mediated response.
23 Therefore, our results reveal
that both PI4K isoforms can supply phosphoinositide sub-
strate during receptor tyrosine kinase activation of PLCg.
Furthermore, our results in COS-7 cells do not indicate any
correlation between reduced PLC signaling and inhibited cell
proliferation.
On the other hand, we found a correlation between Akt
phosphorylation and cell survival, both of which are under the
control of PI4Ks but not through PI(4,5)P2 synthesis. RNAi
studies showed that when PI4K loss induced apoptosis, this
was always accompanied by a change in Akt phosphorylation
status known to correlate with decreased survival of that
particular cell line. Speciﬁcally, decreased Akt phosphoryla-
tion in COS-7 cells in response to PI4KIIa loss resulted in
caspase-mediated apoptosis, whereas in MDA-MB-231 cells,
enhanced Akt phosphorylation induced by loss of either
PI4KIIa or PI4KIIIb led to substantial cell death. These
opposing effects on Akt phosphorylation cannot be explained
by depletion of PI(4,5)P2 levels, which were reduced in both
cell types by loss of either PI4K isoform.
We were able to further differentiate the effects of changing
total cellular PI4P and PI(4,5)P2 from effects on vesicular
trafﬁcking by overexpression of kinase-inactive PI4KIIa. This
well-characterized approach induces defective endosomal
trafﬁcking without measurable changes to total cellular
PI(4,5)P2 levels.
14,16,33 Overexpression of kinase-inactive
PI4KIIa in COS-7 cells resulted in reduced Akt activation in
response to EGF. Although it is not yet technically possible to
visualize the pool of PI4P synthesized by PI4KIIa, there is
evidence for microdomains of PI4KIIa activity on intracellular
membranes.
34–36 These are not recognized by available
PI4P-speciﬁc PH domain reporters or current anti-PI4P
antibody-staining protocols,
37 but are nevertheless important
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Figure 5 Knockdown of PI4KIIa or PI4KIIIb in MDA-MB-231 cells. MDA-MB-
231 cells were mock transfected or transfected with PI4KIIa or PI4KIIIb siRNA.
(a)TimecourseofPI4Kknockdown.Cellswereanalyzedbyimmunoblottingagainst
PI4KIIa, PI4KIIIb orGAPDHat 0, 24,48 and72haftertransfection.Representative
blot from ﬁve experiments are shown. (b) Western blot of dilution series of non-
transfected COS-7 or MDA-MB-231 cell lysates showing relative levels of PI4Ks
compared with GAPDH. Blot shown is representative of two independent
experiments. Note that differences in expression are most evident at 1:4 dilution
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Cell Death and Diseasein the maintenance of PI4K-dependent vesicular trafﬁck-
ing.
15,16 This leads us to infer that cell-speciﬁc antiapoptotic
vesicular trafﬁcking pathways rather than gross changes to
phosphoinositide metabolism underlie PI4K-dependent cell
survival. In concordance with this idea, there are now several
examples of sustained prosurvival signaling that are depen-
dent on endosomal signaling outputs (reviewed in Murphy
et al.
38).
We show here that PI4KIIa inhibition may be an effective
way of generally inhibiting cell survival. This differs from the
scenario with PI3Ks where all p110 subunits can contribute
toward cell survival,
39,40 and where class 1A PI3K and PTEN
status are also important.
7 Although the antiapoptotic function
of PI4KIIIb appears to be more cell type-dependent, the
resultspresentedherearesigniﬁcantinthatMDA-MB-231are
a triple-negative breast cancer cell line that expresses neither
hormone receptors nor HER2 and are normal for class 1A
PI3K and PTEN.
7 Interestingly, enhanced Akt phosphorylation
in MDA-MB-231 cells is associated with reduced cell
proliferation.
31 This subclass of breast cancers is not targeted
by hormonal therapies or anti-HER2 Herceptin antibody, and
their proliferation is insensitive to Akt inhibition.
7 Hence,
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Figure 6 Loss of PI4KIIa or PI4KIIIb induces apoptosis and reduces proliferation in MDA-MB-231 cells. MDA-MB-231 cells were mock transfected or transfected with
PI4KIIa or PI4KIIIb siRNA. (a) Effects of PI4KIIa or PI4KIIIb depletion on PARP cleavage as analyzed by immunoblotting. Representative blot from two independent
experiments is shown. (b and c) Analysis of RNAi-treated cells for apoptosis using the TUNEL assay. Representative confocal images and apoptotic cell counts from two
independent experiments. Scale bar¼50mm. (d) Effects of PI4KIIa or PI4KIIIb depletion on cell proliferation. Live cell counts were determined at 0, 24, 48 and 72h after
transfection. Data presented are means±S.E.M. of four independent experiments. *Po0.05 for PI4KIIa and PI4KIIIb knockdown
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therapeutic strategy to treat such malignancies. Therefore,
PI4Ks indirectly modulate Akt signaling in a manner consis-
tentwith cell survival,but theisoform dependencyneedstobe
considered on a cell- or tissue-speciﬁc basis.
Materials and Methods
Materials. Mouse EGF was purchased from Sigma-Aldrich (Dorset, UK).
Anti-PI4KIIa monoclonal antibody 1C4 was described previously.
27 Anti-PI4KIIIb
was obtained from BD Biosciences (Oxford, UK). Anti-EGFR was from Cell
Signaling Technologies (Hertfordshire,UK)andfromBDBiosciences.Thefollowing
primary antibodies were from Cell Signaling Technologies: anti-pEGFR(Tyr1173),
anti-pEGFR(Tyr845), anti-PLCg1, anti-pPLCg1(Ser1248), anti-pPLCg1(Tyr783),
anti-Akt, anti-pAkt(Ser473), anti-caspase-3, anti-PARP, anti-b-actin, anti-lamin and
anti-GAPDH. Horseradish peroxidase (HRP)-conjugated anti-mouse and anti-rabbit
secondary antibodies were from Cell Signaling Technologies. Dulbecco’s modiﬁed
Eagle’s medium (DMEM), fetal bovine serum (FBS), penicillin and streptomycin
were purchased from PAA Laboratories (Somerset, UK). [
32P]phosphate was from
Perkin Elmer (Cambridge, UK). Other reagents were from Sigma-Aldrich.
Lipofectamine was from Invitrogen (Paisley, UK).
Cell culture. Cells were maintained at 371C in a humidiﬁed incubator at 5%
CO2. Cells were cultured in DMEM containing stable glutamine, 10% FBS, 50 IU/ml
penicillin and 50mg/ml streptomycin. For experiments involving overexpression of
eGFP-PI4KIIa or kinase-inactive eGFP-(K152A)PI4KIIa, cells were transfected
using lipofectamine 24h before EGF addition, according to the manufacturer’s
instructions.
RNAi. Three siRNA duplexes targeting human PI4KIIa were used in combination
(oligos 1 and 2 are described in Wang et al.,
14 and oligo 3 was used in Minogue
et al.
15). The siRNA duplex targetinghuman PI4KIIIb was described in Balla et al.
32
Oligos were synthesized by Euroﬁns MWG Operon (London, UK). Cells were
seeded in penicillin/streptomycin-free medium the day before transfection, onto
12-well plates for EGF stimulation experiments (4.0 10
4 cells, 1ml medium per
well) or onto 6-well plates (9.9 10
4 cells, 2.5ml medium per well) for proliferation
assays. Transfections were performed using Oligofectamine (Invitrogen) according
to the manufacturer’s instructions. In all, 3ml Oligofectamine and 120pmol total
siRNA were added per well of a 12-well plate. Equivalent amounts were used for
cells on 6-well plates. After 24h, cells were transfected a second time in the same
manner, and were analyzed up to 72h after the ﬁrst transfection.
Stimulation with EGF. After 72h of transfection, cells were serum starved in
DMEMwith25mMHEPES(pH7.4)foratleast3hbeforestimulationwith100ng/ml
EGF in the same medium, in a 371C water bath. Stimulations were stopped by
adding the same volume of hot 2X SDS-PAGE sample buffer onto the cells. The
samples were scraped, harvested, heated to 701C for 5min and sonicated.
Immunoblotting. Samples were resolved by SDS-PAGE, transferred onto
PVDF membrane, whichwas blocked with 5% Marvel or 5% bovine serum albumin,
probed with primary antibodiesin blocking buffer. After washing and incubationwith
HRP-conjugated secondary antibody, protein bands were visualized by
chemiluminescence (ECL from GE Healthcare, Buckinghamshire, UK, or
Immobilon Western Chemiluminescent HRP Substrate from Millipore,
Hertfordshire, UK) and exposed to X-ray ﬁlm. For quantiﬁcation of western blots,
ﬁlms were scanned with a Bio-Rad GS-800 Calibrated Densitometer into image
software PD Quest 7.3.0 (Bio-Rad, Hertfordshire, UK) at the highest resolution.
Phospholipid analysis. Cell monolayers growing in 12-well plates were
transfected with siRNA. After 72h, they were labeled with [
32P]phosphate
(0.7–1MBq/well) for 2h at 371C in phosphate-free and serum-free DMEM
containing 25mM HEPES (pH 7.4). Cells were stimulated by the addition of EGF
and reactions were stopped by the addition of an equal volume of ice-cold 1M HCl.
Following two washes with 1M HCl, the cell monolayers were scraped and
transferred to an eppendorf tube. Phosphoinositides were extracted and separated
by thin layer chromatography (TLC) as previously described.
34 TLC plates were
imaged and radioactive spots quantiﬁed using a Typhoon phosphorimager
(GE Healthcare) within the linear range of the instrument. To correct for RNAi-
induced differences in cell number, a matched non-radiolabeled well from each
RNAi condition was harvested in SDS-PAGE sample buffer. As a measure for
protein content, the samples were analyzed by western blotting and densitometry
for GAPDH. This permitted the normalization of [
32P]phospholipid content against
protein content.
Proliferation assay. Cells treated with siRNA were stained with trypan blue
andviablecellswerecountedinahemocytometerat0,24,48and72haftertheﬁrst
transfection. Separate wells were lysed in 2X SDS-PAGE sample buffer, scraped
and harvested for immunoblotting.
TUNEL assay. MDA-MB-231 cells grown on glass coverslips were treated with
siRNA. After 72h, the cells were ﬁxed with 4% (v/v) formaldehyde for 10min on ice.
They were then permeabilized and TUNELlabeled for DNA strand breaks using the
in situ Cell Death Detection Kit (Roche, West Sussex, UK) according to the
manufacturer’s protocol. After counterstaining with Hoechst 33342 (Invitrogen), the
coverslipsweremountedin ProLongGoldanti-fadereagent(Invitrogen).Cellswere
imaged using a Zeiss LSM 510 Meta laser-scanning confocal microscope system
(Carl Zeiss Ltd, Hertfordshire, UK) under a  20 objective as described
previously.
15 Fields of cells were picked at random and gain settings were
identical for each condition. A total of 1100–1400 cells were counted from 10–11
ﬁelds for each condition.
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Figure 7 Effects of PI4KIIa or PI4KIIIb knockdown in MDA-MB-231 cells on
EGF signaling. MDA-MB-231 cells were mock transfected or transfected with
PI4KIIa or PI4KIIIb siRNA. (a) PI4KIIa or PI4KIIIb knockdown enhances Akt
phosphorylation without affecting EGFR phosphorylation, PLCg phosphorylation or
EGFR levels. After 72h of transfection, the cells were stimulated with 100ng/ml
EGF or vehicle control for 10min and analyzed by immunoblotting. Representative
blots from at least two independent experiments are shown. (b) Effects of PI4K
siRNA on [
32P]-labeled PI4P and [
32P]-labeled PI(4,5)P2. After 72h of siRNA
transfection, cells were labeled with [
32P]phosphate and harvested. [
32P]-labeled
lipidswereanalyzedbyTLC.Datapresentedarefromtwoindependentexperiments
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32P]phospholipid data were analyzed by two-tailed Student’s
t-test and live cell counts from proliferation assays by one-way ANOVA with
Dunnett’sposttest,usingGraphPadPrism5forWindows(GraphPadSoftware,San
Diego, CA, USA).
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